Vera Therapeutics Inc
VERA
Company Profile
Business description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact
8000 Marina Boulevard
Suite 120
BrisbaneCA94005
USAT: +1 650 770-0077
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
224
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
stocks
Overvalued ASX share hurt by normalising conditions
Investors overly optimisitc about future prospects.
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,101.30 | 44.40 | 0.49% |
| CAC 40 | 7,950.18 | 14.59 | -0.18% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 74.80 | 0.16% |
| FTSE 100 | 9,682.57 | 53.21 | -0.55% |
| HKSE | 26,362.85 | 121.02 | 0.46% |
| NASDAQ | 23,004.54 | 49.46 | -0.21% |
| Nikkei 225 | 50,860.14 | 583.77 | 1.16% |
| NZX 50 Index | 13,595.75 | 3.46 | -0.03% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,826.40 | 34.60 | 0.39% |
| SSE Composite Index | 3,995.85 | 1.70 | -0.04% |